ZGNX - Zogenix posts new data from FINTEPLA study in patients with Dravet syndrome

Zogenix (ZGNX) announces new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA (fenfluramine) on patients with Dravet syndrome.Caregivers of patients who received FINTEPLA through either the Phase 3 clinical trial program or the U.S. early access program were recruited to participate in one-on-one semi-structured interviews to discuss the benefits of fenfluramine for the child with Dravet syndrome.The majority of caregivers reported feeling less stress, anxiety, and depression, with 62% of employed parents missing less work.Seizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and shorter recovery time when seizure did occur.Non-Seizure benefits most commonly noted include improvements in executive functions such as cognition, learning, and problem solving, as well as mood, sleep quality, and motor function.In three Phase 3 studies, FINTEPLA has showed the ability to provide transformational and durable seizure reduction for many Dravet syndrome patients whose

For further details see:

Zogenix posts new data from FINTEPLA study in patients with Dravet syndrome